VACCINATION OF BALB/C MICE AGAINST CUTANEOUS LEISHMANIASIS USING LIPOSOMES INCORPORATED WITH RECOMBINANT MAJOR SURFACE GLYCOPROTEIN OF LEISHMANIA (RGP63)

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

JAFARI M.R.; AREFIE A.; SADRI K.; AMANI M.; MAHBOUDI F.

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: PHARMACEUTICAL SCIENCES Year:2004 | Volume:- | Issue:2 Page(s): 41-60

Download Full-Text

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Verion

View:

1,049

Download:

Cites:

Information Journal Paper

Title

VACCINATION OF BALB/C MICE AGAINST CUTANEOUS LEISHMANIASIS USING LIPOSOMES INCORPORATED WITH RECOMBINANT MAJOR SURFACE GLYCOPROTEIN OF LEISHMANIA (RGP63)

Author(s)

Keywords

CUTANEOUS LEISHMANIASISQ3

LIPOSOMEQ2

RGP63Q3

CELLULAR IMMUNITYQ3

DTHQ3

Abstract

The objective of this study was to formulate LIPOSOME preparations loaded with recombinant major surface metalloproteinase glycoprotein of Leishmania (rGP63) to selectively induce cell mediated immunity (CMI) in susceptible BALB/c mice and protect the mice against challenge with virulent L. Major. LIPOSOMEs containing RGP63 was prepared as dehydration-rehydration vesicles and composed of DPPC (Dipalmitoylphosphatidylcholin) and cholesterol (Chol) (DRV-DPPC/Chol-rGP63 7:2 molar ratio). To this fonnulation, DOPE (Dioleoylphosphatidylethanolamine) (DRV-DPPC/DOPE/Chol-rGP63 7:1:2 molar ratio) and stearylamine (SA) (DRYDPPC/ SA/Chol-rGP63 7:2:2 molar ratio) were added to produce fusogenic and positively charged LIPOSOMEs, respectively. Another formulation had all the lipid ingredients (DRV-DPPC/DOPE/SAlChol-rGP63, 7:1:2:2 molar ratio). All the LIPOSOME formulations were heterogeneous in size, ranging from 0.1 to 1.5 µm, but their encapsulation (ate was high (46-52%). LIPOSOME preparations containing RGP63 (2µg), RGP63 (2µg) by itself (PBS-rGP63), PBS (Phosphate buffer saline), and a control LIPOSOME (DRV-DPPC/Cho 17:2 molar ratio) were injected subcutaneously (Se) three times in groups of 10 female BALB/c mice with three weeks intervals. Three weeks later the mice were tested for delayed type hypersensitivity (DTH) by injecting 2 µg of RGP63 SC to the left footpads; and for comparison the right footpads were injected with PBS. After 24, 48 and 72 hours the footpad thickness was measured on both foot pads. One weak after the DTH test, the mice were challenged with virulent L. major promastigotes (1 x 106/50 µL) SC to the left footpads and the footpad thickness was measured for 10 weeks. The results of DTH test indicated that among different groups, the DRV-DPPC/DOPE/Chol-rGP63 had the greatest positive DTH response compare d to the control groups (p <0.01). The DTH response of the other liposomal formulations containing RGP63 and PB S-rGP63 were also positive (p<0.05); however, it was less. In the challenge test, the DRV-DPPC/DOPE/Chol-rGP63 had a complete protective effect (p<0.001). The DRY-DPPC/Chol-rGP63 had also a good protective effect (p<0.001) but it was less than the DRV-DPPC/DOPE/Chol-rGP63. The DRV-DPPC/SAlChol-rGP63 had a little protective effect that was not statistically significant (p>0.05), DRV-DPPC/DOPE/SAlChol-rGP63 and PBS-rGP63 showed only partial protection (p<0.05). These results indicate that DRV-DPPC/DOPE/Chol-rGP63 could be a suitable immunoadjuvant for RGP63 to induce selective CMI in susceptible BALB/c mice and protect the mice against CUTANEOUS LEISHMANIASIS.

Cites

No record.

References

No record.

Cite

APA: Copy

JAFARI, M.R., AREFIE, A., SADRI, K., AMANI, M., & MAHBOUDI, F.. (2004). VACCINATION OF BALB/C MICE AGAINST CUTANEOUS LEISHMANIASIS USING LIPOSOMES INCORPORATED WITH RECOMBINANT MAJOR SURFACE GLYCOPROTEIN OF LEISHMANIA (RGP63) . PHARMACEUTICAL SCIENCES, -(2), 41-60. SID. https://sid.ir/paper/357014/en

Vancouver: Copy

JAFARI M.R., AREFIE A., SADRI K., AMANI M., MAHBOUDI F.. VACCINATION OF BALB/C MICE AGAINST CUTANEOUS LEISHMANIASIS USING LIPOSOMES INCORPORATED WITH RECOMBINANT MAJOR SURFACE GLYCOPROTEIN OF LEISHMANIA (RGP63) . PHARMACEUTICAL SCIENCES[Internet]. 2004;-(2):41-60. Available from: https://sid.ir/paper/357014/en

IEEE: Copy

M.R. JAFARI, A. AREFIE, K. SADRI, M. AMANI, and F. MAHBOUDI, “VACCINATION OF BALB/C MICE AGAINST CUTANEOUS LEISHMANIASIS USING LIPOSOMES INCORPORATED WITH RECOMBINANT MAJOR SURFACE GLYCOPROTEIN OF LEISHMANIA (RGP63) ,” PHARMACEUTICAL SCIENCES, vol. -, no. 2, pp. 41–60, 2004, [Online]. Available: https://sid.ir/paper/357014/en

Related Journal Papers